Imlunestrant: First Approval door Susan J. Keam (6594447)

Onderwerpen:

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Canc... door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer door Jamunarani Veeraraghavan (16461809)

Onderwerpen:

Data Sheet 1_Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.xlsx door Andrea Aran (11711939)

Onderwerpen:

Supplementary file 1_Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.docx door Andrea Aran (11711939)

Onderwerpen:

Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine door Karama Asleh (15030080)

Onderwerpen:

Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States door Laura E. Stevens (14961009)

Onderwerpen:

Figure 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States door Laura E. Stevens (14961009)

Onderwerpen:

Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States door Laura E. Stevens (14961009)

Onderwerpen:

Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Supplementary Table S5 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States door Laura E. Stevens (14961009)

Onderwerpen:

Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States door Laura E. Stevens (14961009)

Onderwerpen:

Figure 3 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen: